Skip to main content

STERIS plc guidance

  • STE · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$260.67−0.48%Close 17 Nov 2026 · Market value $25.22B

In its results release of 4 Nov 2026 (Q2 FY2027), STERIS plc gave 1 forecast in figures, among them EPS (adjusted) of $11.35 to $11.55 for FY2027. Over the last two years, results landed above the company's own last range 2 of 4 times, within it 2 and below it 0.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q2 FY2027 results, 4 Nov 2026

MeasurePeriodGuidanceAs stated
EPS · AdjustedFY2027$11.35 to $11.55Adjusted earnings per diluted share are now anticipated to be in the range of $11.35 to $11.55, an increase from prior expectations of $11.10 to $11.30

Source: the company's earnings release.

Guidance against results above 2 · within 2 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
Organic revenue growthFY2027+6% to +7%Given once—To come
EPS · AdjustedFY2027$11.35 to $11.55Raised once—To come
Free cash flowFY2027About $800MGiven once—To come
Capital expendituresFY2027About $450MRaised once—To come
Capital expendituresFY2026About $375MUnchanged$369MWithin the range
Tax rateFY2026About 24%Unchanged25.04%Above the range
Capital expendituresFY2025About $360MUnchanged$370MAbove the range
Tax rateFY2025About 23%Unchanged23.2%Within the range

STE in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.